Biotechnology

BIODLINK-B

BIODLINK-B released FY2025 Q3 earnings on March 18, 2026 (BJT) with actual revenue of HKD 141.29 M and EPS of HKD -0.0787

BIODLINK-B released FY2025 9 Months Earnings on March 18 (BJT), with actual revenue of HKD 670.91 M and EPS of HKD -0.0726

BIODLINK-B released FY2025 Q4 earnings on March 18 During-Market (BJT), actual revenue HKD 143.73 M, actual EPS HKD -0.0819

BIODLINK-B released FY2025 annual earnings on March 18 During-Market (BJT), actual revenue HKD 817.15 M (forecast HKD 1.505 B), actual EPS HKD -0.1512

WuXi Advanced Therapies Extends Tender Offer Deadline for Dongyao Pharmaceuticals

BIODLINK-B to Release FY2025 Earnings on March 18 During-Market (BJT), Forecast Revenue HKD 1.505 B

WuXi Xullink Acquires East 曜 Pharmaceutical at a High Premium

WuXi BODYLOGIC Expects Significant Growth in Revenue and Net Profit in 2025 and Announces Acquisition of Tonex Pharmaceuticals

WuXi Bodylogics Makes a Cash Offer at HKD4 per Share to Acquire Oncologie

BIODLINK-B released FY2025 Q1 earnings on August 12 (BJT) with actual revenue of HKD 261.93 M and EPS of HKD 0.0053

BIODLINK-B released FY2025 Q2 earnings on August 12 After-Market (BJT), actual revenue HKD 267.69 M, actual EPS HKD 0.003

BIODLINK-B released FY2025 Semi-Annual Earnings on August 12 After-Market (BJT), Actual Revenue: HKD 529.62 M, Actual EPS: HKD 0.006

BIODLINK-B to Release FY2025 Semi-Annual Earnings on August 12, 2025 (BJT)

East 曜 Pharma-B proposes to change its English name

Ecolab's Q1 Revenue Grew by 13% to RMB 252 Million

Announcement of Changes in the Board Members of Dongyao Pharmaceutical-B

TOT BIOPHARM-B released FY2024 Q3 earnings on March 11 (BJT) with actual revenue of 320.19 M HKD and EPS of 0.0024 HKD

TOT BIOPHARM-B released FY2024 9 Months Earnings on March 11 (BJT), with actual revenue of 882 M HKD and EPS of 0.0494 HKD

Dongyao Pharmaceutical-B (01875) Announces 2024 Results, Revenue Exceeds 1 Billion, First Time Profit Turnaround

TOT BIOPHARM-B released FY2024 annual earnings on March 11 After-Market (BJT), actual revenue 1.189 B HKD (forecast 1.171 B HKD), actual EPS 0.0518 HKD

CENTRAL DEV H

FAMEGLOW

ZHONGSHENJIANYE

TJCD

NEW GONOW RV

REALWAY CAPITAL

ZXZN QI-HOUSE

51WORLD

EASYHOLD GROUP

CH CITY INFRA

01875

BioDlink International Company Limited has announced its board composition and the roles of its members, emphasizing structured corporate governance. The board includes an executive chairperson, a non-executive director, and independent non-executive directors. Key committees include Audit and Connected Transactions Review, chaired by Xin Fan, and Strategy and ESG, led by Ulf Grawunder. The governance structure aligns with Hong Kong listing standards, with a focus on balancing management input and independent oversight. The company is listed under stock code 1875 and operates in the biopharmaceutical sector.

Tip Ranks

BioDlink Sets Out Board Composition and Key Committee Roles

00178

00538

In the context of ongoing conflicts, Hong Kong stocks fluctuated slightly, and investors faced a choice: to buy short positions for hedging or to reduce positions to cope with the market. SA SA INT'L (178) and Dongyao Pharmaceutical (1875) performed well, with the latter reaching a new high. AJISEN (CHINA) (538) announced a turnaround to profitability, with a dividend yield of 13 cents, and cash levels exceeding market value, making it a good hedging option

Stheadline

SA SA INT'L

AJISEN (CHINA)

13 Basis Points: A Good Hedge in Turbulent Times | Tang Niu

02268

Dongyao Pharmaceutical (1875) saw its stock price rise over 16% in the afternoon, reaching HKD 5.25. According to Sing Tao Daily, the company is expected to become a new stock that skyrockets due to a change in ownership. WuXi XDC (2268) has made a voluntary offer to acquire all shares of Dongyao Pharmaceutical, with the transaction expected to be completed in the first half of 2026. Dongyao Pharmaceutical plans to leverage WuXi XDC's brand and platform advantages to advance international operations, enhance production capacity and supply chain resilience, while also increasing R&D investment in CDMO to improve competitiveness. The projected operating revenue for 2025 is expected to be RMB 748 million, a decrease of 32%

WUXI XDC

Dongyao Pharmaceutical surged 17% in the afternoon, with "Star Market Strategy" first predicting explosive growth potential

Dongyao Pharmaceutical-B announced its performance for the fiscal year 2025, with operating revenue of 748 million RMB, a year-on-year decrease of 32%. Among this, product sales revenue was 488 million RMB, down 44%, mainly due to intensified market competition. It recorded a loss of 100 million RMB, compared to a net profit of 34.76 million RMB in the previous year, turning from profit to loss; loss per share was 14 cents. No dividend was declared

AASTOCKS

"Performance" Dongyao Pharmaceutical reported a full-year loss of 100 million yuan, turning from profit to loss

08279

01907

01812

02661

00746

02656

02788

03336

00325

AGTECH HOLDINGS(08279) rose 23.23%, with a trading turnover 22.3 Million HKD, and a year-to-date rose 203.5%. CHINA RISUN GP(01907) rose 15.85%, with a trading turnover 1.5 Billion HKD, and a year-to-date rose 45.6%. CHENMING PAPER(01812) rose 13.04%, with a trading turnover 23.1 Million HKD, and a year-to-date rose 66.7%.

Top Gainers&Losers

AGTECH HOLDINGS

CHINA RISUN GP

CHENMING PAPER

QINGSONG HEALTH

L & M CHEMICAL

160 HEALTH

CHUANGXIN IND

JU TENG INTL

BLOKS

Top 10 HK Stock Gainers (3.12)

Dongyao Pharmaceutical - B announced its unaudited financial data for the fiscal year 2025, with operating revenue of 748 million RMB, a year-on-year decrease of 31.9%. It recorded a net loss of 100 million RMB, compared to a net profit of 34.76 million RMB in the previous year, turning from profit to loss

Dongyao Pharmaceutical's net loss for the fiscal year 2025 is 100 million RMB

WuXi XDC Cayman Inc. has sent out an offer document for a voluntary cash takeover of TOT BIOPHARM International Co. Ltd. (HK:1875), excluding shares already held by the offeror. The offer starts on 12 February 2026, with key deadlines extending to mid-March. The latest analyst rating for TOT BIOPHARM is a Hold, with a price target of HK$4.50. TOT BIOPHARM focuses on developing oncology and biologic therapies and is listed on the Hong Kong Stock Exchange, with a market cap of HK$3.25B.

WuXi XDC Dispatches Offer Document for Cash Takeover of TOT BIOPHARM

BioDlink International Company Limited has appointed Grand Moore Capital Limited as the independent financial adviser for its Independent Board Committee regarding WuXi XDC Cayman Inc.'s voluntary conditional cash offer to acquire all shares not owned by the offeror. The adviser will assess the fairness of the offer terms and provide recommendations for shareholders. Investors are cautioned that the offer's completion is subject to conditions. The latest analyst rating for TOT BIOPHARM International Co. Ltd. (HK:1875) is a Hold with a price target of HK$4.50.

BioDlink Appoints Independent Adviser for WuXi XDC’s Conditional Takeover Offer

BIODLINK-B(01875.HK)